- Home
- CB vs VCEL Comparison
CB vs VCEL Comparison
Compare CB & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CB
- VCEL
- Stock Information
- Founded
- CB 1985
- VCEL 1989
- Country
- CB Switzerland
- VCEL United States
- Employees
- CB N/A
- VCEL N/A
- Industry
- CB Property-Casualty Insurers
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CB Finance
- VCEL Health Care
- Exchange
- CB Nasdaq
- VCEL Nasdaq
- Market Cap
- CB 117.0B
- VCEL 2.1B
- IPO Year
- CB 1993
- VCEL 1997
- Fundamental
- Price
- CB $285.24
- VCEL $42.55
- Analyst Decision
- CB Buy
- VCEL Strong Buy
- Analyst Count
- CB 15
- VCEL 8
- Target Price
- CB $308.00
- VCEL $62.00
- AVG Volume (30 Days)
- CB 1.5M
- VCEL 439.0K
- Earning Date
- CB 07-22-2025
- VCEL 07-31-2025
- Dividend Yield
- CB 1.34%
- VCEL N/A
- EPS Growth
- CB N/A
- VCEL 521.85
- EPS
- CB 20.78
- VCEL 0.05
- Revenue
- CB $56,307,000,000.00
- VCEL $238,541,000.00
- Revenue This Year
- CB N/A
- VCEL $23.03
- Revenue Next Year
- CB $6.03
- VCEL $24.52
- P/E Ratio
- CB $13.95
- VCEL $724.21
- Revenue Growth
- CB 8.74
- VCEL 14.80
- 52 Week Low
- CB $251.42
- VCEL $37.39
- 52 Week High
- CB $306.91
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- CB 43.98
- VCEL 51.57
- Support Level
- CB $282.22
- VCEL $40.53
- Resistance Level
- CB $288.94
- VCEL $43.51
- Average True Range (ATR)
- CB 4.01
- VCEL 1.77
- MACD
- CB -0.60
- VCEL -0.08
- Stochastic Oscillator
- CB 16.63
- VCEL 42.62
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.